Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Looking at molecular makeup and MRIs to characterise infant ependymoma.
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Looking into whether survivors of childhood cancer are at risk of severe infections.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Developing better models of rhabdomyosarcoma to test available treatments.
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene